skip to page content
About
(current)
Technology
Technology Platform
Gene Therapy
Gene Editing
Therapeutic Focus
Publications & Presentations
Patients &
Families
Patients & Families
Expanded Access Policy
Clinical Trials
News &
Events
Careers
Investors
bigger
Created with Sketch.
News & Events
News & Events
For media inquiries, please email
cmayfield@homologymedicines.com
SIGN UP FOR NEWS ALERTS
News
& Events
Current News & Events
|
Archived News & Events
09/06/2022
Homology Medicines Appoints Albert Seymour, Ph.D., Chief Executive Officer
08/15/2022
Homology Medicines Reports Second Quarter 2022 Financial Results, Recent Highlights and Provides Business Update
08/11/2022
Homology Medicines Announces Optimized, In Vivo Gene Therapy Candidate for the Treatment of Metachromatic Leukodystrophy
07/05/2022
Homology Medicines Announces Peer-Reviewed Publication on Novel Discovery of AAVHSC with Robust Distribution to the Central Nervous System and Peripheral Organs with Low Affinity for the Liver
06/29/2022
Homology Medicines to Present at Upcoming Conferences on its Gene Editing and Gene Therapy Programs for PKU
06/13/2022
Homology Medicines Announces FDA Lifted Clinical Hold on pheNIX Gene Therapy Trial for PKU
05/18/2022
Homology Medicines Presents Details of Optimized HMI-103 Nuclease-Free Gene Editing Candidate Featuring Integrated Liver-Specific Promoter to Maximize Long-Term Expression
05/16/2022
Homology Medicines Reports First Quarter 2022 Financial Results and Recent Highlights
05/02/2022
Homology Medicines Announces Upcoming Presentation on Optimized In Vivo Gene Editing Candidate HMI-103 with First Details of Unique Mechanism of Action at ASGCT Annual Meeting
04/21/2022
Homology Medicines Announces Promotion of Albert Seymour, Ph.D., to President
03/23/2022
Homology Medicines Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
03/10/2022
Homology Medicines Announces Closing of Deal Leveraging its Internal Process Development and CMC Capabilities Through Newly Formed AAV Manufacturing Innovation Business with Oxford Biomedica
03/03/2022
Homology Medicines to Participate in Upcoming Investor Conferences
02/18/2022
Homology Medicines Provides an Update on pheNIX Gene Therapy Trial for Adults with PKU
02/10/2022
Homology Medicines Announces Presentations on HMI-203 Investigational Gene Therapy for Hunter Syndrome and Broad Applicability of AAVHSC Platform for Lysosomal Storage Disorders at the 18th Annual WORLDSymposium™ Meeting
01/27/2022
Oxford Biomedica broadens leading viral vector offerings by incorporating Homology Medicines’ established AAV capabilities into a newly formed AAV Manufacturing and Innovation Business in the U.S. with Homology Medicines as 20% owner
11/15/2021
Homology Medicines Reports Third Quarter 2021 Financial Results and Recent Highlights
11/03/2021
Homology Medicines to Participate in Upcoming Investor Conferences
10/21/2021
Homology Medicines Announces Presentations Across Gene Therapy and Gene Editing Programs, including GTx-mAb, at European Society of Gene & Cell Therapy Meeting
10/20/2021
Homology Medicines Announces Presentation of Data Supporting Clinical Programs in MPS II and PKU, including Nonclinical and Patient-Focused Research, at American Society of Human Genetics Meeting
10/18/2021
Homology Medicines Initiates Clinical Trial for HMI-203, a One-Time Investigational Gene Therapy Candidate for Adults with MPS II (Hunter Syndrome)
10/12/2021
Homology Medicines Announces World’s First Gene Editing Clinical Trial for PKU
